Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
949.62B
Market cap949.62B
Price-Earnings ratio
35.60
Price-Earnings ratio35.60
Dividend yield
0.63%
Dividend yield0.63%
Average volume
3.89M
Average volume3.89M
High today
$996.49
High today$996.49
Low today
$983.50
Low today$983.50
Open price
$991.28
Open price$991.28
Volume
3.92M
Volume3.92M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

Eli Lilly(LLY) stock is priced at $987.00, giving the company a market capitalization of 949.62B. It carries a P/E multiple of 35.60 and pays a dividend yield of 63.0%.

On 2026-05-07, Eli Lilly(LLY) stock traded between a low of $983.50 and a high of $996.49. Shares are currently priced at $987.00, which is +0.4% above the low and -1.0% below the high.

The Eli Lilly(LLY)'s current trading volume is 3.92M, compared to an average daily volume of 3.89M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

LLY News

Simply Wall St 44m
Eli Lilly Indiana Expansion Supports Obesity Pipeline And Undervalued Story

Eli Lilly (NYSE:LLY) is committing $4.5b to expand its Indiana manufacturing footprint. The investment includes the Lebanon Advanced Therapies facility, the co...

Eli Lilly Indiana Expansion Supports Obesity Pipeline And Undervalued Story
TipRanks 4h
Eli Lilly commits additional $4.5B across Indiana manufacturing sites

Eli Lilly (LLY) and Company announced an additional $4.5B investment across two of its three Lebanon sites-bringing the company’s total Indiana capital expansio...

TipRanks 6h
Trump Highlights Eli Lilly’s $4.5 Billion Genetic Medicine Push: Potential Ripple Effects Across Health Care and Biotech ETFs - TipRanks

...

Trump Highlights Eli Lilly’s $4.5 Billion Genetic Medicine Push: Potential Ripple Effects Across Health Care and Biotech ETFs - TipRanks

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
12.1%
Sell
3%

More LLY News

Barron's 23h
Novo Stock Rises After Earnings. It’s Taking the Weight-Loss Drug Fight to Eli Lilly.

Biotech and Pharma Earnings Report Novo Stock Rises After Earnings. It’s Taking the Weight-Loss Drug Fight to Eli Lilly. In this article NVO LLY Novo Nordisk ra...

Novo Stock Rises After Earnings. It’s Taking the Weight-Loss Drug Fight to Eli Lilly.
Sherwood News 1d
Novo beats Q1 estimates, raises full-year guidance

Novo beats Q1 estimates, raises full-year guidance Novo Nordisk rose in premarket trading after it reported first quarter earnings results that beat Wall Stree...

Novo beats Q1 estimates, raises full-year guidance
Benzinga 2d
Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence

Omvoh Shows Durable Disease Clearance Disease clearance was evaluated among patients who achieved clinical remission with Omvoh at one year in the LUCENT-2 main...

Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence
24/7 Wall St. 2d
Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125% By Thomas Richmond Published May 4, 4:50PM EDT Quick Read Morning Brew Daily hosts a...

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%
Nasdaq 3d
The Most Surprising Thing About Eli Lilly's Impressive Revenue Growth: Just How Much More Potential There Is

Key Points Eli Lilly's GLP-1 drugs generated nearly $13 billion in revenue last quarter. The company still has tremendous opportunities in international marke...

The Most Surprising Thing About Eli Lilly's Impressive Revenue Growth: Just How Much More Potential There Is
CNBC 3d
Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance

Key Points Novo Nordisk's Wegovy pill has created another boom in the GLP-1 drug market. Eli Lilly recently introduced its Foundayo pill for weight loss, three...

Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance
TipRanks 3d
Eli Lilly tells RBC liver case ‘not reasonably related to Foundayo’

RBC Capital notes that Eli Liily shares were down as much as 3% in pre-market trading amid reports of a single FAERS hepatic failure case reported for Foundayo,...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.